TACE and sorafenib: A good marriage?

Journal of Clinical Oncology

Volumn 29, Issue 30, 2011, Pages 3949-3952

  Abou Alfa, Ghassan K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; PLACEBO; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL TUMOR; HUMAN; INOPERABLE CANCER; INVASIVE PROCEDURE; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE;

EID: 80054728433     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.9651     Document Type: Editorial

References (48)

1. Olweny CL, Toya T, Katongole-Mbidde E, et al.: Treatment of hepatocellular carcinoma with adriamycin: Preliminary communication. Cancer 36:1250-1257, 1975
2. Ihde DC, Kane RC, Cohen MH, et al.: Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 61:1385-1387, 1977 (Pubitemid 8204112)
3. Vogel CL, Bayley AC, Brooker RJ, et al.: A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 39:1923-1929, 1977 (Pubitemid 8129022)
4. Johnson PJ, Williams R, Thomas H, et al.: Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1:1006-1009, 1978 (Pubitemid 8342858)
5. Williams R, Melia WM: Liver tumours and their management. Clinical Radiology 31:1-11, 1980
6. Barbare JC, Ballet F, Petit J, et al.: Hepatocellular carcinoma with cirrhosis: Treatment with doxorubicin - Phase II evaluation [in French]. Bulletin du Cancer 71:442-445, 1984 (Pubitemid 15198773)
7. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al.: Doxorubicin (75 mg/m2) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 68:487-491, 1984 (Pubitemid 14134096)
8. Sciarrino E, Simonetti RG, Le Moli S, et al.: Adriamycin treatment for hepatocellular carcinoma: Experience with 109 patients. Cancer 56:2751-2755, 1985 (Pubitemid 16216280)
9. Yeo W, Mok TS, Zee B, et al.: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532-1538, 2005 (Pubitemid 41631953)
10. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
11. Cheng AL, Kang YK, Chen Z, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25- 34, 2009
12. Cheng A, Kang Y, Lin D, et al.: Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 29:256s, 2011 (suppl; abstr 4000)
13. Thomas MB, Morris JS, Chadha R, et al.: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843-850, 2009. Erratum in J Clin Oncol 27:3263, 2009
14. Bevacizumab and erlotinib or sorafenib as first-line therapy in treating patients with advanced liver cancer. http://www.clinicaltrials.gov/ct2/show/ NCT00881751?term=nct00881751&rank=1
15. Abou-Alfa GK, Capanu M, Saltz L: In response to Pazo Cid, RA, et al.: Doxorubicin and sorafenib in the treatment of hepatocellular carcinoma. JAMA 305:781, 2011
16. Sorafenib tosylate with or without doxorubicin hydrochloride in treating patients with locally advanced or metastatic liver cancer. http://www. clinicaltrials .gov/ct2/show/NCT01015833?term=nct01015833&rank=1
17. Llovet JM, Real MI, Montaña X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359:1734-1739, 2002 (Pubitemid 34607087)
18. Lo CM, Ngan H, Tso WK, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171, 2002 (Pubitemid 34454013)
19. Pelletier G, Roche A, Ink O, et al.: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181-184, 1990
20. Madden MV, Krige JE, Bailey S, et al.: Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 34:1598-1600, 1993 (Pubitemid 23341855)
21. Group d'Etude et de Traitement de Carcinome Hepatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261, 1995
22. Pelletier G, Ducreux M, Gay F, et al.: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. J Hepatol 29:129-134, 1998 (Pubitemid 28307992)
23. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429-442, 2003 (Pubitemid 36152543)
24. Cammà C, Schepis F, Orlando A, et al.: Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 224:47-54, 2002 (Pubitemid 34680374)
25. Simonetti RG, Liberati A, Angiolini C, et al.: Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 8:117-136, 1997 (Pubitemid 27112878)
26. Mathurin P, Rixe O, Carbonell N, et al.: Overview of medical treatments in unresectable hepatocellular carcinoma; an impossible meta-analysis? Aliment Pharmacol Ther 12:111-126, 1998 (Pubitemid 28059978)
27. Pawlik TM, Reyes DK, Cosgrove D, et al.: Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29:3960-3967, 2011
28. Llovet JM, Brú C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liv Dis 19:329-338, 1999
29. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
30. Tsuchida Y, Therasse P: Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37:1-3, 2001 (Pubitemid 32613627)
31. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 42:1208-1236, 2005 (Pubitemid 43112690)
32. Dufour JF, Hoppe H, Heim MH, et al.: Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: Results of a phase I study. Oncologist 15:1198-1204, 2010
33. Chemoembolization with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. http://www.clinicaltrials .gov/ct2/show/NCT01004978?term=nct01004978&rank=1
34. Lencioni R, Zou J, Leberre M, et al.: Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). J Clin Oncol 28:15s, 2010 (suppl; abstr TPS178)
35. Li X, Feng GS, Zheng CS, et al.: Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10:2878-2882, 2004 (Pubitemid 39303010)
36. Wang B, Xu H, Gao ZQ, et al.: Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 49:523-529, 2008
37. Gupta S, Kobayashi S, Phongkitkarun S, et al.: Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 41:516-521, 2006 (Pubitemid 44284186)
38. Sergio A, Cristofori C, Cardin R, et al.: Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103:914-921, 2008 (Pubitemid 351506379)
39. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000
40. Jiang H, Meng Q, Tan H, et al.: Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer 121:416-424, 2007 (Pubitemid 46917712)
41. Kudo M, Imanaka K, Chida N, et al.: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer [Epub ahead of print June 9, 2011]
42. Strebel BM, Dufour JF: Combined approach to hepatocellular carcinoma: A new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 8:1743-1749, 2008
43. Forner A, Ayuso C, Varela M, et al.: Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 115:616-623, 2009
44. Choi H, Charnsangavej C, Faria SC, et al.: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759, 2007 (Pubitemid 46797957)
45. Choi H, Charnsangavej C, de Castro Faria S, et al.: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183:1619-1628, 2004 (Pubitemid 44210530)
46. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60, 2010
47. Abou-Alfa GK, Schwartz L, Ricci S, et al.: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300, 2006 (Pubitemid 46630787)
48. Abou-Alfa GK, Zhao B, Capanu M, et al.: Tumor necrosis as a correlate for response in subgroup of patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. ESMO 2008, Stockholm, Sweden. Ann Oncol 19:viii178, 2008 (suppl 8; abstr 547P)